Solésence Reports Record $62.1M Revenue for 2025, Full-Year Net Income Halves
SLSN sits 15% above its 52-week low of $0.78.
Summary
Solésence reported mixed financial results for the fourth quarter and full-year 2025. The company achieved record full-year revenue of $62.1 million, a 19% increase year-over-year, driven by growth in consumer products. However, full-year net income significantly declined to $1.8 million from $4.2 million in 2024, and gross margin compressed from 31% to 26%. For the fourth quarter, revenue was flat at $12.5 million, but the company swung to a net income of $0.2 million from a $0.6 million loss in the prior year period, with gross margin improving to 27%. Management highlighted a new strategic initiative, "Transform & Transcend," aimed at driving sustainable, profitable growth. Traders will be watching if the Q4 profitability improvements can be sustained and if the strategic initiatives can reverse the full-year margin and net income declines.
At the time of this announcement, SLSN was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.5M. The 52-week trading range was $0.78 to $16.56. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.